Floatz logo

Dtpw-Hbv/Hib-Menac Conjugate Vaccine

Whole Cell Pertussis

GlaxoSmithKlinevaccinePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Whole Cell Pertussis cohort.

Asset / SponsorPhaseRating
Whole-Cell Pertussis Vaccine
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 3BB
HUMAN IMMUNOGLOBULINS
IWK Health Centre
Phase 3B

Same molecule, other indications

Dtpw-Hbv/Hib-Menac Conjugate Vaccine is also rated in:

haemophilus infectious diseaseDormant
B
Indicative ·
57 / 100
View asset →
tetanusDormant
B
Indicative ·
57 / 100
View asset →
hepatitis B virus infectionDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →